18732998. BISPECIFIC ANTI-HUMAN CD20/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE simplified abstract (Hoffmann-La Roche Inc.)

BISPECIFIC ANTI-HUMAN CD20/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE

Organization Name

Hoffmann-La Roche Inc.

Inventor(s)

Harald Duerr of Starnberg (DE)

Sebastian Fenn of Achmuehle/Eurasburg (DE)

Ulrich Goepfert of Penzberg (DE)

Sabine Imhof-jung of Krailling (DE)

Christian Klein of Bonstetten (CH)

Laurent Lariviere of Westendorf (DE)

Michael Molhoj of Muenchen (DE)

Joerg Thomas Regula of Muenchen (DE)

Petra Rueger of Penzberg (DE)

Wolfgang Schaefer of Mannheim (DE)

BISPECIFIC ANTI-HUMAN CD20/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE - A simplified explanation of the abstract

This abstract first appeared for US patent application 18732998 titled 'BISPECIFIC ANTI-HUMAN CD20/HUMAN TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE

Simplified Explanation

This patent application describes bispecific anti-human CD20/human transferrin receptor antibodies and their methods of use.

Key Features and Innovation

• Development of bispecific antibodies targeting CD20 and transferrin receptor.
• Ability to target two different antigens simultaneously for enhanced therapeutic effects.
• Potential for improved treatment outcomes in diseases such as cancer.

Potential Applications

The technology can be applied in the treatment of various diseases, including cancer, by targeting specific antigens simultaneously.

Problems Solved

This technology addresses the limitations of traditional monoclonal antibodies by targeting multiple antigens for more effective treatment.

Benefits

• Enhanced therapeutic effects due to targeting multiple antigens.
• Potential for improved treatment outcomes in diseases like cancer.
• Increased specificity and efficacy in targeting diseased cells.

Commercial Applications

The bispecific antibodies can be used in the development of novel cancer therapies, potentially leading to new treatment options in the pharmaceutical market.

Questions about Bispecific Anti-Human CD20/Human Transferrin Receptor Antibodies

What are the potential implications of using bispecific antibodies in cancer treatment?

Bispecific antibodies have the potential to enhance the efficacy of cancer treatment by targeting multiple antigens simultaneously, leading to improved outcomes for patients.

How do bispecific antibodies differ from traditional monoclonal antibodies in terms of targeting mechanisms?

Bispecific antibodies can target two different antigens simultaneously, offering a more precise and effective approach compared to traditional monoclonal antibodies.

Original Abstract Submitted

Herein are provided bispecific anti-human CD20/human transferrin receptor antibodies and methods of using the same.